Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-14

FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride), expanding its approved extended-release formulation for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JENTADUETO XR (Linagliptin and metformin hydrochloride)

Snippet

SUPPL AP for JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE)